See Our Latest Insights
on the impacts of COVID-19.

$115 Million

Syndax Pharmaceuticals

Follow-on Offering

Bookrunner, April 2020

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline in key areas of unmet need related to cancer. The Company's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer.

More Like This

May 2020
$40 Million

Follow-on Offering

Lead Left Bookrunner

View Details
May 2020
$175 Million

Follow-on Offering

Lead Left Bookrunner

View Details
May 2020
$862 Million

Follow-on Offering

Bookrunner

View Details